Evidence map›Paper›PMID 33483615›Full record

ArticleLeukemia2021

T-ALL can evolve to oncogene independence.

Hesham Abdulla, Anh Vo, Benjamin J Shields, Tenae J Davies, Jacob T Jackson, Raed Alserihi, Elizabeth M Viney, Tin Wong, Feng Yan, Nicholas C Wong and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase DNAJB1-PRKACA.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Hesham Abdulla *Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0001-8745-2293
Anh Vo *Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.
Benjamin J Shields *Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.
Tenae J Davies *Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.
Jacob T JacksonWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-6396-2739
Raed AlserihiWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Elizabeth M VineyWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Tin WongAustralian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.
Feng YanAustralian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-8848-1739
Nicholas C WongAustralian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-4393-7541
Lisa DemoenDepartment of Biomolecular Medicine, Ghent University, Ghent, Belgium.
David J CurtisAustralian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-9497-0996
Warren S AlexanderWalter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Pieter Van VlierbergheDepartment of Biomolecular Medicine, Ghent University, Ghent, Belgium.ORCID http://orcid.org/0000-0001-9063-7205
Ross A DickinsAustralian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia.
Matthew P McCormackAustralian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia. matthew.mccormack@monash.edu.ORCID http://orcid.org/0000-0003-1536-5611
Australian Centre for HIV and Hepatitis Virology Research · AUWalter and Eliza Hall Institute of Medical Research · AUGhent University · BEThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The majority of cases of T-cell acute lymphoblastic leukemia (T-ALL) contain chromosomal abnormalities that drive overexpression of oncogenic transcription factors. However, whether these initiating oncogenes are required for leukemia maintenance is poorly understood. To address this, we developed a tetracycline-regulated mouse model of T-ALL driven by the oncogenic transcription factor Lmo2. This revealed that whilst thymus-resident pre-Leukemic Stem Cells (pre-LSCs) required continuous Lmo2 expression, the majority of leukemias relapsed despite Lmo2 withdrawal. Relapse was associated with a mature phenotype and frequent mutation or loss of tumor suppressor genes including Ikzf1 (Ikaros), with targeted deletion Ikzf1 being sufficient to transform Lmo2-dependent leukemias to Lmo2-independence. Moreover, we found that the related transcription factor TAL1 was dispensable in several human T-ALL cell lines that contain SIL-TAL1 chromosomal deletions driving its overexpression, indicating that evolution to oncogene independence can also occur in human T-ALL. Together these results indicate an evolution of oncogene addiction in murine and human T-ALL and show that loss of Ikaros is a mechanism that can promote self-renewal of T-ALL lymphoblasts in the absence of an initiating oncogenic transcription factor.

Indexed as

Gene Expression Regulation, LeukemicAdaptor Proteins, Signal TransducingAnimalsIkaros Transcription FactorLIM Domain ProteinsMiceMice, Inbred C57BLMice, KnockoutOncogenesPrecursor T-Cell Lymphoblastic Leukemia-LymphomaAdaptor Proteins, Signal TransducingIkaros Transcription FactorLIM Domain ProteinsLmo2 protein, mouseZfpn1a1 protein, mouse

Identifiers

PMID33483615
OpenAlexW3124938480

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.